NCT04140396

Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia

A Prospective Comparison of Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The current cornerstone of pain control for rib fractures is oral and intravenous opioids, especially in the form of patient-controlled analgesia (IV PCA), which are are associated with multiple adverse effects including sedation, respiratory depression, cough suppression, and increased risk of delirium. In the past few decades, intravenous lidocaine infusion (IVL) has emerged as a new tool in the arsenal of multimodal analgesia. Multiple randomized clinical trials have indicated that IVL is overall well tolerated and have shown other beneficial effects such as anti-inflammatory properties. To this date, there have been no published randomized clinical trials (RCT) evaluating the effectiveness of IVL in management of traumatic rib fracture pain. Therefore, the purpose of this study is to evaluate whether IV Lidocaine infusion can provide improved pain control as demonstrated by decreased OME consumption at 24 and 48 hours compared to placebo in adult patients with acute traumatic rib fractures.

Conditions

• Rib Fractures

Interventions

Type	Name	Description
DRUG	Saline infusion	Normal saline infusion at 10mL/hour
DRUG	Lidocaine infusion	Lidocaine infusion at 1.0mg/kg/hr

Timeline

• Start date: 2020-02-10
• Primary completion: 2020-11-09
• Completion: 2020-11-09
• First posted: 2019-10-25
• Last updated: 2023-11-30
• Results posted: 2023-11-30

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study